Systems Regeneration for Spinal Cord Injury

New Scientific Publication Released

We are pleased to share our latest review article exploring a new systems-level approach to one of regenerative medicine’s most complex challenges: spinal cord injury (SCI).

A Systems-Level Therapeutic Platform Integrating Neural Progenitors, Mitochondrial Medicine, and Organ-Specific Biologics

By Prof. Dr. Mike K.S. Chan, Prof. Dr. Michelle B.F. Wong, Krista Casazza, and Jonathan RT Lakey

About the Publication:

Spinal cord injury is not simply a localized neurological lesion. It involves a complex network of interconnected challenges, including neuronal loss, mitochondrial dysfunction, chronic inflammation, vascular compromise, extracellular matrix remodeling, and failure of endogenous repair. This complexity may help explain why single-modality regenerative approaches have struggled to produce consistent functional recovery.

This review proposes a systems regeneration framework that brings together three complementary therapeutic pillars:

• Developmentally specified neural precursor/progenitor cells to support circuit reconstruction, remyelination, and host–graft integration
• Mitochondrial-directed therapeutics to restore cellular bioenergetics, reduce oxidative stress, and enhance the survival of both native and transplanted cells
• Organ-specific regenerative biologics, including Nano Organo Peptides (NOPs) and Mito Organelle (MO) preparations, designed to support tissue-specific signaling involved in inflammation, angiogenesis, extracellular matrix remodeling, metabolism, and endogenous repair.

Why It Matters

Rather than targeting a single pathway, this framework views SCI as a systems-level failure of regeneration that may require coordinated restoration of developmental identity, mitochondrial competence, and a supportive regenerative microenvironment.

The article presents the European Wellness regenerative platform as a hypothesis-driven translational model integrating these complementary strategies, while emphasizing that further molecular characterization, standardized potency testing, biomarker development, and controlled clinical trials are needed to validate its therapeutic potential.

📖 Read the full publication here:
https://european-wellness.eu/publications/a-systems-level-therapeutic-platform-integrating-neural-progenitors-mitochondrial-medicine-and-organ-specific-biologics/

Other Publications: https://european-wellness.eu/publications